Zentiva (BSE:SCD) Other Long-Term Liabilities: lei6 Mil (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSE:SCD Zentiva SA BSE:SCD
10 GF Score
Price lei4.52
View Full Analysis

What is Zentiva Other Long-Term Liabilities?

Zentiva BSE:SCD 10 Other Long-Term Liabilities is lei6 Mil as of Mar. 2025. GuruFocus rates BSE:SCD with a GF Score™ of 10/100.

Zentiva's other long-term liabilities for the quarter that ended in Mar. 2025 was lei6 Mil.

Zentiva's quarterly other long-term liabilities declined from Sep. 2024 (lei6 Mil) to Dec. 2024 (lei4 Mil) but then increased from Dec. 2024 (lei4 Mil) to Mar. 2025 (lei6 Mil).

Zentiva's annual other long-term liabilities declined from Dec. 2022 (lei13 Mil) to Dec. 2023 (lei7 Mil) and declined from Dec. 2023 (lei7 Mil) to Dec. 2024 (lei4 Mil).

Zentiva Other Long-Term Liabilities Related Terms

Zentiva Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Zentiva's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zentiva Other Long-Term Liabilities Chart

Zentiva Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.82 8.64 12.69 6.82 4.28

Zentiva Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.35 6.91 5.83 4.28 6.29
BSE:SCD
10GF Score
Zentiva SA BSE:SCD
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zentiva Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of lei6 Mil mean?
Zentiva (BSE:SCD) has a Other Long-Term Liabilities of lei6 Mil as of Mar. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zentiva and its competitors.
Is Zentiva's Other Long-Term Liabilities too high?
Zentiva's current Other Long-Term Liabilities is lei6 Mil. Overall, Zentiva has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Zentiva's Other Long-Term Liabilities compare to ZTS and VTRS?
Zentiva's Other Long-Term Liabilities of lei6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Drug Manufacturers company?
A good Other Long-Term Liabilities depends on the Drug Manufacturers industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Zentiva and its competitors. Zentiva's current Other Long-Term Liabilities is lei6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zentiva stock overvalued right now?
Zentiva (BSE:SCD) has a current Other Long-Term Liabilities of lei6 Mil. The current Other Long-Term Liabilities is lei6 Mil. Zentiva's overall GF Score™ is 10/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Zentiva (BSE:SCD), the current Other Long-Term Liabilities is lei6 Mil as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zentiva Business Description

Address No. 50, Theodor Pallady Boulevard, Sector 3, Bucharest, ROU, 032266
Zentiva SA is a Romania-based producer of medicines on the local market. The product portfolio of Zentiva SA includes more than 126 products for human use, such as solids (tablets, capsules, and pellets), generic products, and injectable solutions. The company provides products for therapeutic areas such as Cardiovascular diseases, Anti-inflammatory and pain-relieving medications, urologists, Blood diseases, Gastrointestinal and metabolic disorders, Central nervous system, Medicines against infections, and Diseases of the respiratory system.
10GF Score

Get the complete analysis for BSE:SCD

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei4.52
Price